New Alzheimer’s drug offers hope for end to ‘terrifying’ psychosis affecting half of all patients

Updated on - Written by

Reported in The Telegraph  : A new drug promises to spare hundreds of thousands of Alzheimer’s sufferers from “terrifying” hallucinations and paranoia, researchers have announced.

Scientists have successfully tested the first medicine capable of treating psychosis, which affects around half of patients with the disease, without the devastating side-effects caused by current drugs. Published in the Lancet Neurology, the trial of pimavanserin offers particular hope to those with advanced psychosis, which doctors often describe as the most distressing symptom of Alzheimer’s.

Currently people with dementia rely on mainstream antipsychotics, however these can double the speed at which brain function deteriorates, increase the risk of falls and lead to sedation. Figures indicate they also cause 1,660 unnecessary strokes and 1,800 unnecessary deaths in the UK every year. By contrast, pimavanserin, which targets a specific nerve receptor in the brain, was shown to significantly improve psychosis symptoms without the normal side-effects.

Researchers at the University of Exeter Medical School tested the drug on 90 patients with Alzheimer’s disease, giving a placebo to a further 90.


British Geriatrics Society


+ sources

Health Canal avoids using tertiary references. We have strict sourcing guidelines and rely on peer-reviewed studies, academic researches from medical associations and institutions. To ensure the accuracy of articles in Health Canal, you can read more about the editorial process here

Written by:

Healthcanal Staff

Medically reviewed by:

HealthCanal Editorial team is a team of high standard writers, who qualified the strict entrance test of Health Canal. The team involves in both topic researching and writting, which are under supervision and controlled by medical doctors of medical team.

PubMed Central

Database From National Institute Of Health

U.S National Library of Medicine
Go to source